<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018458</url>
  </required_header>
  <id_info>
    <org_study_id>013-154</org_study_id>
    <nct_id>NCT02018458</nct_id>
  </id_info>
  <brief_title>Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer</brief_title>
  <official_title>Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and feasibility of combining&#xD;
      cyclin B1/WT-1/CEF (antigen)-loaded DC vaccination with preoperative chemotherapy.&#xD;
&#xD;
      The secondary objectives of this trial are to determine pathologic complete response rates;&#xD;
      disease-free survival; to assess immune biomarkers of immunity (antigen-specific CD8+ T cell&#xD;
      immunity and TH2 T cells) in breast cancer biopsy specimens and blood samples in patients&#xD;
      receiving DC vaccinations; and to assess the feasibility of immunizing LA TNBC and ER+/HER2-&#xD;
      BC patients with patient-specific tumor antigens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent studies have shown that human breast cancers can be immunogenic, and that enhancing&#xD;
      the immune effector function already present may augment the cytotoxic effects of standard&#xD;
      therapies.&#xD;
&#xD;
      vaccination remains the most attractive strategy because of its expected inducement of both&#xD;
      therapeutic T cell immunity (effector T cells) and protective T cell immunity (tumor-specific&#xD;
      memory T cells that can control tumor relapse). Several clinical studies have now&#xD;
      demonstrated that immunity against tumor antigens can be enhanced in cancer patients by&#xD;
      vaccination with ex vivo-generated tumor antigen-loaded dendritic cells (DCs). This strategy&#xD;
      capitalizes on the unique capacity of DCs to prime lymphocytes and to regulate and maintain&#xD;
      immune responses.&#xD;
&#xD;
      Our goals are to boost T cell immunity targeted against breast cancer utilizing a tumor&#xD;
      antigen-loaded DC vaccine, to enhance chemotherapy effectiveness and decrease tumor&#xD;
      metastagenicity, and to decrease the recurrence rates of LA TNBC and ER+/HER2- BC. Patients&#xD;
      will be treated with a combination of antigen-loaded DC vaccinations along with standard&#xD;
      preoperative chemotherapy, to improve immunogenicity and to increase the pCR rate achieved&#xD;
      with standard therapy. The trial will consist of 2 patient cohorts: TNBC and ER+/HER2- BC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">September 18, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of DC Vaccine Combined With Chemotherapy</measure>
    <time_frame>4 years</time_frame>
    <description>Toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 . This will include all patients (eligible and ineligible) who receive at least 1 inoculation of DC vaccine therapy. This safety population will also be used for the summaries and analysis of all safety parameters (drug exposure, tables of adverse events information, including serious adverse events, etc.).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2 did not enroll any patients.&#xD;
The pathologic specimen will be graded per the tumor regression grading schema provided by the University of Texas MD Anderson Cancer Center &quot;Residual Cancer Burden Calculator&quot; at http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3. The following parameters are required from pathologic examination in order to calculate RCB: largest 2 dimensions of residual tumor bed in the breast; entire largest cross-sectional area of residual tumor bed; percentage of the tumor bed area that contains carcinoma; percentage of carcinoma in tumor bed that is in situ; number of positive (metastatic) lymph nodes; largest diameter of largest nodal metastasis. A pathologic complete response is defined as NO pathologic evidence of invasive disease in the breast or axillary lymph nodes. RCB-I (minimal cancer burden); RCB-II (moderate burden); and RCB-III (extensive burden).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2, &quot;ER+/HER2- BC: DC vaccine+preop chemo patients&quot; did not enroll any patients with these hormone receptor criteria.&#xD;
Analysis of disease-free survival (&quot;DFS&quot;, reported in months) was calculated from the first day of treatment up to 36 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LA TNBC: DC vaccine+Preop chemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER+/HER2-BC:DC vaccine+Preop chemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LA TNBC: DC vaccine+Preop chemo</intervention_name>
    <description>LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.</description>
    <arm_group_label>LA TNBC: DC vaccine+Preop chemo</arm_group_label>
    <other_name>DC Vaccine - Dendritic Cell Vaccine</other_name>
    <other_name>Preop chemo: Doxorubicin</other_name>
    <other_name>Preop chemo: cyclophosphamide</other_name>
    <other_name>Preop chemo: Paclitaxel</other_name>
    <other_name>Preop chemo: Carboplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ER+/HER2-BC:DC vaccine+Preop chemo</intervention_name>
    <description>ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.</description>
    <arm_group_label>ER+/HER2-BC:DC vaccine+Preop chemo</arm_group_label>
    <other_name>DC Vaccination - Dendritic cell vaccination</other_name>
    <other_name>Preop chemo - doxorubicin</other_name>
    <other_name>Preop chemo - cyclophosphamide</other_name>
    <other_name>Preop chemo - paclitaxel</other_name>
    <other_name>Preop chemo: Carboplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        - Inclusion Criteria:&#xD;
&#xD;
        A patient will be considered for enrollment in this study if all of the following criteria&#xD;
        are met:&#xD;
&#xD;
          1. Female patients ≥18 years of age.&#xD;
&#xD;
          2. Have either:&#xD;
&#xD;
               1. locally advanced TNBC defined as invasive ductal cancer; ER- tumors with &lt;10% of&#xD;
                  tumor nuclei immunoreactive; PR- tumors with &lt;10% of tumor nuclei immunoreactive;&#xD;
                  T3 or T4 disease, regardless of nodal status (T2 disease is eligible if there are&#xD;
                  positive lymph nodes present by physical exam or imaging evaluation or&#xD;
                  histological evaluation, OR&#xD;
&#xD;
               2. High-risk ER+ breast cancer defined as grade 3 invasive ductal or mixed&#xD;
                  ductal/lobular cancers, or grade 2 with Ki67 ≥20%; node positive as evidenced by&#xD;
                  physical exam or imaging evaluation or histological evaluation.&#xD;
&#xD;
          3. HER2- negative breast cancer. If HER2-, it is defined as follows:&#xD;
&#xD;
               1. FISH-negative (FISH ratio &lt;2.0), or&#xD;
&#xD;
               2. IHC 0-1+, or&#xD;
&#xD;
               3. IHC 2+ AND FISH-negative (FISH ratio&lt;2.0)&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
          5. Adequate hematologic function, defined by:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &gt;1500/mm3&#xD;
&#xD;
               2. Platelet count ≥100,000/mm3&#xD;
&#xD;
               3. Hemoglobin &gt;9 g/dL (in the absence of red blood cell transfusion)&#xD;
&#xD;
          6. Adequate liver function, defined by:&#xD;
&#xD;
               1. AST and ALT ≤2.5 x the upper limit of normal (ULN)&#xD;
&#xD;
               2. Total bilirubin ≤1.5 x ULN&#xD;
&#xD;
          7. Adequate renal function, defined by:&#xD;
&#xD;
             a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥60 ml/min&#xD;
&#xD;
          8. Patients with previous history of invasive cancers (including breast cancer) are&#xD;
             eligible if definitive treatment was completed more than 5 years prior to initiating&#xD;
             current study treatment, and there is no evidence of recurrent disease.&#xD;
&#xD;
          9. Eligible for treatment with paclitaxel, doxorubicin, cyclophosphamide and&#xD;
             carboplatine.&#xD;
&#xD;
         10. Patient must be accessible for treatment and follow-up.&#xD;
&#xD;
         11. Patients must be willing to undergo research biopsies to obtain breast cancer tissue&#xD;
             for whole exome sequencing and evaluation of tumor immune microenvironment.&#xD;
&#xD;
         12. All patients must be able to understand the investigational nature of the study and&#xD;
             give written informed consent prior to study entry.&#xD;
&#xD;
               -  Exclusion Criteria:&#xD;
&#xD;
        A patient will be ineligible for inclusion in this study any of the following criteria are&#xD;
        met:&#xD;
&#xD;
          1. Evidence of metastatic disease on bone scan and CT scan of chest/abdomen (or PET CT&#xD;
             scan). Patients with intrathoracic metastatic adenopathy are eligible.&#xD;
&#xD;
          2. Active infection or unexplained fever &gt;38.5°C during screening.&#xD;
&#xD;
          3. Active infections including viral hepatitis and HIV.&#xD;
&#xD;
          4. Active asthma or other condition requiring steroid therapy.&#xD;
&#xD;
          5. Autoimmune disease including lupus erythematosus or rheumatoid arthritis. Topical or&#xD;
             inhaled corticosteroids are allowed.&#xD;
&#xD;
          6. Patients who are currently receiving or who have received previous systemic therapy&#xD;
             for breast cancer (eg, chemotherapy, antibody therapy, targeted agents).The use of an&#xD;
             LHRH agonist during chemotherapy in premenopausal women who wish to preserve ovarian&#xD;
             function is allowed, but is not required.&#xD;
&#xD;
          7. Women who are pregnant or lactating. All patients with reproductive potential must&#xD;
             agree to use effective contraception from time of study entry until at least 3 months&#xD;
             after the last administration of study drug.&#xD;
&#xD;
          8. Have a NYHA Class III or IV CHF or LVEF &lt;55%. Patients with significant cardiac&#xD;
             disease history within 1 year or ventricular arrhythmias requiring medication are also&#xD;
             excluded.&#xD;
&#xD;
          9. Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation such as:&#xD;
&#xD;
               1. severe impaired lung functions as defined as spirometry and DLCO that is 50% of&#xD;
                  the normal predicted value and/or O2 saturation that is 88% or less at rest on&#xD;
                  room air&#xD;
&#xD;
               2. uncontrolled diabetes as defined by fasting serum glucose &gt;1.5 x ULN&#xD;
&#xD;
               3. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class&#xD;
                  C).&#xD;
&#xD;
         10. History of any other disease, physical examination finding, or clinical laboratory&#xD;
             finding giving reasonable suspicion of a disease or condition that contraindicates use&#xD;
             of an investigational drug, or that might affect interpretation of the results of this&#xD;
             study, or render the patient at high risk for treatment complications.&#xD;
&#xD;
         11. Any other investigational or anti-cancer treatments while participating in this study.&#xD;
&#xD;
         12. Any other cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce O'Shaughnessy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Health Care System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <results_first_submitted>February 28, 2020</results_first_submitted>
  <results_first_submitted_qc>February 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2020</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dendritic cell vaccine</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Carboplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02018458/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Arm &quot;ER+/HER2- BC: DC vaccine + preop chemo&quot; is not included in these results, as no participants were enrolled in this arm with these hormone receptor criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LA TNBC: DC Vaccine+Preop Chemo</title>
          <description>LA TNBC patients will be enrolled to receive DC vaccinations during the 24 weeks of standard preoperative dose-dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel and carboplatin (TCb) chemotherapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LA TNBC: DC Vaccine+Preop Chemo</title>
          <description>LA TNBC patients will be enrolled to receive DC vaccinations during the 24 weeks of standard preoperative dose-dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel and carboplatin (TCb) chemotherapy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of DC Vaccine Combined With Chemotherapy</title>
        <description>Toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 . This will include all patients (eligible and ineligible) who receive at least 1 inoculation of DC vaccine therapy. This safety population will also be used for the summaries and analysis of all safety parameters (drug exposure, tables of adverse events information, including serious adverse events, etc.).</description>
        <time_frame>4 years</time_frame>
        <population>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2, &quot;ER+/HER2- BC: DC vaccine+preop chemo patients&quot; did not enroll any patients with these hormone receptor criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>LA TNBC: DC Vaccine+Preop Chemo</title>
            <description>LA TNBC patients will be enrolled to receive DC vaccinations during the 24 weeks of standard preoperative dose-dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel and carboplatin (TCb) chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of DC Vaccine Combined With Chemotherapy</title>
          <description>Toxicities will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 . This will include all patients (eligible and ineligible) who receive at least 1 inoculation of DC vaccine therapy. This safety population will also be used for the summaries and analysis of all safety parameters (drug exposure, tables of adverse events information, including serious adverse events, etc.).</description>
          <population>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2, &quot;ER+/HER2- BC: DC vaccine+preop chemo patients&quot; did not enroll any patients with these hormone receptor criteria.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Complete Response Rate</title>
        <description>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2 did not enroll any patients.&#xD;
The pathologic specimen will be graded per the tumor regression grading schema provided by the University of Texas MD Anderson Cancer Center &quot;Residual Cancer Burden Calculator&quot; at http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3. The following parameters are required from pathologic examination in order to calculate RCB: largest 2 dimensions of residual tumor bed in the breast; entire largest cross-sectional area of residual tumor bed; percentage of the tumor bed area that contains carcinoma; percentage of carcinoma in tumor bed that is in situ; number of positive (metastatic) lymph nodes; largest diameter of largest nodal metastasis. A pathologic complete response is defined as NO pathologic evidence of invasive disease in the breast or axillary lymph nodes. RCB-I (minimal cancer burden); RCB-II (moderate burden); and RCB-III (extensive burden).</description>
        <time_frame>1 year</time_frame>
        <population>All eligible patients who have received at least 1 inoculation of DC vaccine therapy will be assessed for pathologic complete response.</population>
        <group_list>
          <group group_id="O1">
            <title>LA TNBC: DC Vaccine+Preop Chemo</title>
            <description>LA TNBC patients will be enrolled to receive DC vaccinations during the 24 weeks of standard preoperative dose-dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel and carboplatin (TCb) chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate</title>
          <description>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2 did not enroll any patients.&#xD;
The pathologic specimen will be graded per the tumor regression grading schema provided by the University of Texas MD Anderson Cancer Center &quot;Residual Cancer Burden Calculator&quot; at http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3. The following parameters are required from pathologic examination in order to calculate RCB: largest 2 dimensions of residual tumor bed in the breast; entire largest cross-sectional area of residual tumor bed; percentage of the tumor bed area that contains carcinoma; percentage of carcinoma in tumor bed that is in situ; number of positive (metastatic) lymph nodes; largest diameter of largest nodal metastasis. A pathologic complete response is defined as NO pathologic evidence of invasive disease in the breast or axillary lymph nodes. RCB-I (minimal cancer burden); RCB-II (moderate burden); and RCB-III (extensive burden).</description>
          <population>All eligible patients who have received at least 1 inoculation of DC vaccine therapy will be assessed for pathologic complete response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>pathologic complete response (pCR)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Residual Cancer Burden 1 (RCB1)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Residual Disease (RD)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2, &quot;ER+/HER2- BC: DC vaccine+preop chemo patients&quot; did not enroll any patients with these hormone receptor criteria.&#xD;
Analysis of disease-free survival (&quot;DFS&quot;, reported in months) was calculated from the first day of treatment up to 36 months.</description>
        <time_frame>36 months</time_frame>
        <population>All eligible patients who have received at least 1 inoculation of DC vaccine therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>LA TNBC: DC Vaccine+Preop Chemo</title>
            <description>LA TNBC patients will be enrolled to receive DC vaccinations during the 24 weeks of standard preoperative dose-dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel and carboplatin (TCb) chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2, &quot;ER+/HER2- BC: DC vaccine+preop chemo patients&quot; did not enroll any patients with these hormone receptor criteria.&#xD;
Analysis of disease-free survival (&quot;DFS&quot;, reported in months) was calculated from the first day of treatment up to 36 months.</description>
          <population>All eligible patients who have received at least 1 inoculation of DC vaccine therapy.</population>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="6.5" upper_limit="26.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 years</time_frame>
      <desc>Results are only reported for Arm 1, &quot;LA TNBC: DC vaccine+preop chemo patients&quot;. Arm 2, &quot;ER+/HER2- BC: DC vaccine+preop chemo patients&quot; did not enroll any patients with these hormone receptor criteria.&#xD;
All Grade 2, 3 and 4 adverse events (AEs), Grades 1 and 2 alopecia, and all grades of neutropenia will be recorded in the CRF throughout the trial.&#xD;
All AEs will be recorded for up to 30 days following the last study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>LA TNBC: DC Vaccine+Preop Chemo</title>
          <description>LA TNBC patients will be enrolled to receive DC vaccinations during the 24 weeks of standard preoperative dose-dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel and carboplatin (TCb) chemotherapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI CTCAE v4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Right atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis of right breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTCAE v4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>flutter in chest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal Reflux</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Parageusia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper Abdomen Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mouth Sores</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Venous Access Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sleep Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain Right Shoulder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insect Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypovitaminosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fungal infection left great toe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Herpes Genitalis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Vibrating Apheresis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right Axilla Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lower Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seroma Left Axilla</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mastalgia right breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthralgias</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tenderness of lymph nodes in right armpit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint popping in hands</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy hands and feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tingling of the Tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy arms and hands</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy bilateral feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intermittent Neuropathy in Toes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Numbness of feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intermittent Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuropathy bilateral lower extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuropathy in hands and feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nodule Left Arm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Right breast cellulitis post reconstruction/expanders surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Right breast focal fibrosis with fat necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seroma bilateral breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Redness Right Breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Left big toe brittle nail</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chemo induced nails bruised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DVT LLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Right upper extremity lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joyce O'Shaughnessy</name_or_title>
      <organization>Baylor Scott and White Health</organization>
      <phone>214-818-8472</phone>
      <email>joyce.oshaughnessy@usoncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

